METTL14 and renal cell adenocarcinoma: According to a new study in 2022 (Shen et al., 2022a), the Lnc-LSG1 was identified as a downstream target of METTL14, and it could promote RCC progression and metastasis by binding to ESRP2 and promoting ESRP2 ubiquitination and degradation.